Metformin decelerates aging clock in male monkeys

Original Article ↗ Hacker News Discussion ↗

New primate research suggesting that the diabetes drug metformin can slow biological aging and preserve brain function is fueling interest in its potential as a general anti-aging therapy. Commenters weigh this promise against mixed evidence from previous animal and human studies, significant side effects (from gastrointestinal issues to rare but serious complications), and uncertainty about whether benefits come from metformin itself or from calorie-restriction-like mechanisms. The conversation broadens to compare metformin with other longevity approaches such as rapamycin, GLP‑1 drugs, fasting, and lifestyle change, and to question whether longer lifespans are desirable if not matched by extended healthspan.

Mechanisms and relation to diet

  • Metformin is described as reducing liver glucose production, increasing insulin sensitivity, and raising GDF15, which suppresses appetite and caloric intake.
  • Some argue its aging effects may largely mimic calorie restriction and weight loss rather than being unique.
  • Others emphasize AMPK–mTORC1 inhibition, autophagy, and broader “starvation mimetic” effects beyond weight control.
  • Several comments link high sugar/carbohydrate intake to metabolic and brain damage, with low‑carb or ketogenic diets cited as reversing type 2 diabetes in some individuals.

Evidence for/against longevity and aging effects

  • The primate study is seen as promising because it addresses earlier doubts based on nematode/mouse data.
  • Critics note mouse Interventions Testing Program results: weak or no lifespan benefit from metformin alone, versus strong effects from rapamycin.
  • A twin-cohort human study is cited as finding no reduction in all‑cause mortality from metformin; earlier claims that diabetics on metformin outlive non‑diabetics are called implausible.
  • Some stress that the new paper focuses on “aging clock” and brain atrophy, not proven lifespan extension.

Side effects and safety concerns

  • Common reports: significant gastrointestinal distress (sometimes months), diarrhea, “emergency” bathroom needs; some find tolerance improves with gradual introduction.
  • Mentioned risks: gastroparesis, metformin‑associated lactic acidosis (potentially high mortality), possible male genital birth defects when taken around conception, and possible cognitive/mood effects in some users.
  • Routine monitoring is described as important due to potential accumulation.

Dosing, trials, and access

  • Monkey dose ~20 mg/kg/day is mapped to common human doses (up to ~2,000 mg/day) already used for diabetes.
  • The TAME aging trial is discussed; it has regulatory green lights but funding problems, allegedly because metformin is off‑patent and not very profitable.
  • Users on high‑dose generic metformin report low cost and good access; concern exists that “longevity hype” could affect pricing, but others note it is old and easy to manufacture.

Comparisons to rapamycin, GLP‑1 drugs, fasting

  • Several argue low‑dose, intermittent rapamycin/rapalogs are more potent and better‑supported mTORC1 inhibitors with strong mouse longevity data.
  • GLP‑1 agonists are framed as powerful, scalable obesity and addiction treatments, with debate over societal implications and psychological side effects.
  • Intermittent fasting is linked mechanistically to mTOR/autophagy, but a cited (not peer‑reviewed) abstract claiming higher cardiovascular mortality with short eating windows is viewed as likely confounded and methodologically weak.

Healthspan vs lifespan and philosophy of aging

  • Many distinguish “living longer” from “aging slower,” emphasizing preserved cognition, function, and delayed disease over mere extra years.
  • The primate finding of reduced brain aging is seen as especially important given dementia concerns.
  • A long subthread debates whether extending life is desirable: some want more time to experience and learn; others, influenced by seeing severe dementia, prioritize a clean, timely death.
  • Some frame extended healthy life as a continuation of civilization’s longstanding effort to transcend “natural” mortality, while critics raise concerns about resource competition, inequality, and extended years of work.

Methodological and species concerns

  • Participants note contradictions between species (mice vs monkeys vs humans) and caution against over‑generalizing.
  • Small sample sizes (e.g., ~12 monkeys), heavy bioinformatics, and lack of large randomized human trials are cited as reasons for skepticism.
  • One commenter flags a general need for caution with studies originating from specific countries, including China.

Open questions and unresolved points

  • Whether metformin’s main benefit for aging is through metabolic disease reduction, direct mTOR/AMPK effects, or other pathways remains unclear.
  • It is unknown if metformin offers net longevity/healthspan gains in non‑diabetics, especially given mixed human and mouse data.
  • Fasting/time‑restricted eating as a metformin alternative or complement is discussed but not resolved; evidence is viewed as mixed and confounded.
  • A patient with neuroendocrine tumors asks about combining metformin with everolimus based on a cancer paper; no concrete structures or tools for patient‑organized trials are provided in the thread.